3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
41
Metastatic Castration-resistant Prostate Cancer
4
Prostatic Diseases
3
Kidney Neoplasms
3
Urogenital Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Neoplasms by Site
2
Neoplasms
2
Genital Neoplasms, Male
2
Carcinoma, Renal Cell
2
Thrombocytopenia
1
Renal Insufficiency
1
Prostate Cancer Metastatic
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasm Metastasis
1
Metastatic Hormone Naive Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Male Urogenital Diseases
1
Liver Neoplasms
1
High-Risk Localized Prostate Cancer
1
Glioma
1
Glioblastoma
1
Genital Diseases, Male
1
Disease
1
Cytopenia
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
proxalutamide
2
Androgen Receptor Antagonists
2
radium Ra 223 dichloride
1
Pluvicto
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
×
Pluvicto
×
Clear all
NCT06943495
2025-09-09
PRODIGY-2
CHU de Quebec-Universite Laval
Phase 1
Recruiting
60 enrolled